The estimated Net Worth of Daniel Menold is at least $1.18 Milione dollars as of 16 January 2024. Mr. Menold owns over 10,000 units of Cymabay Therapeutics Inc stock worth over $324,800 and over the last 8 years he sold CBAY stock worth over $0. In addition, he makes $857,262 as Vice President - Finance at Cymabay Therapeutics Inc.
Sign up
Mr. Menold CBAY stock SEC Form 4 insiders trading
Daniel has made over 8 trades of the Cymabay Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CBAY stock worth $40,500 on 16 January 2024.
The largest trade he's ever made was exercising 21,497 units of Cymabay Therapeutics Inc stock on 15 December 2023 worth over $137,366. On average, Daniel trades about 8,299 units every 131 days since 2017. As of 16 January 2024 he still owns at least 10,000 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Mr. Menold stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Menold biography
Daniel Menold is Vice President - Finance of the Company. He previously served as our Corporate Controller since January 2014. Prior to joining CymaBay, Mr. Menold served as Corporate Controller for technology firm Zoosk, Inc., from 2011 to 2013, where he was responsible for the accounting and financial reporting functions and as Controller and Director of Accounting at Affymetrix, Inc. from 2005 to 2010. Prior to 2005, he held accounting and finance positions of increasing responsibility at public and private life sciences and high technology companies in the Silicon Valley. Earlier in his career, Mr. Menold was at Ernst & Young LLP where he was an audit manager and served on audits of life sciences and high technology companies. Mr. Menold received a M.S. in accounting and B.S. in finance from The University of Virginia McIntire School of Commerce.
What is the salary of Daniel Menold?
As the Vice President - Finance of Cymabay Therapeutics Inc, the total compensation of Daniel Menold at Cymabay Therapeutics Inc is $857,262. There are 3 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.
How old is Daniel Menold?
Daniel Menold is 50, he's been the Vice President - Finance of Cymabay Therapeutics Inc since 2017. There are 14 older and 2 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.
What's Daniel Menold's mailing address?
Daniel's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK, CA, 94560.
Insiders trading at Cymabay Therapeutics Inc
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster e Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
What does Cymabay Therapeutics Inc do?
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
What does Cymabay Therapeutics Inc's logo look like?
Complete history of Mr. Menold stock trades at Cymabay Therapeutics Inc
Cymabay Therapeutics Inc executives and stock owners
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Sujal Shah,
President, Chief Executive Officer, Director -
Charles McWherter,
Senior Vice President, Chief Scientific Officer -
Klara Dickinson,
Chief Regulatory and Compliance Officer -
Daniel Menold,
Vice President - Finance -
Sujal A. Shah,
Pres, CEO & Director -
Dr. Charles A. McWherter Ph.D.,
Chief Scientific Officer -
Paul T. Quinlan,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Robert Wills,
Independent Chairman of the Board -
Kurt von Emster,
Independent Director -
Paul Truex,
Independent Director -
Caroline Loewy,
Independent Director -
Dr. Dennis D. Kim M.B.A., M.D., MBA,
Chief Medical Officer -
Becki Filice,
Sr. VP of Portfolio & Product Leadership -
Klara A. Dickinson-Eason,
Chief Regulatory & Quality Assurance Officer -
Dr. Robert L. Martin,
Sr. VP of Manufacturing & Nonclinical Devel. -
Patrick J. O'Mara,
Sr. VP of Bus. Devel. -
Ken Boehm,
Sr. VP of HR -
Daniel Menold,
VP of Fin. -
Evan A. Stein,
Director -
Robert F. Booth,
Director -
Carl Goldfischer,
Director -
Pol F Boudes,
Chief Medical Officer -
Robert J. Weiland,
Director -
Kirk Rosemark,
V.P. Regulatory & Quality -
Wart Harold Van,
President and CEO -
Emster Kurt Von,
Director -
Thomas G Wiggans,
-
Paul T Quinlan,
General Counsel -
Eric Lefebvre,
-
Harish Shantharam,
Chief Financial Officer -
Lewis J Stuart,
Chief Commercial Officer -
Patrick J. O Mara,
VP, Business Development -
Robert L. Martin,
Sr. Vice President -
Capital Advisors Llc Aghaza...,
-
Edward Penhoet,
Director -
Louis G Lange,
Director -
Hari Kumar,
Director -
Janet Dorling,
-
Dennis D Kim,
Chief Medical Officer